POSSIBILITIES OF THE DIAGNOSIS AND TREATMENT OF THE CERVIX UTERI


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cancer of the cervix uteri (CCU) currently occupies one of the leading places among reproductive system cancers and there is a trend in increased morbidity in many countries of the world. The paper gives data on risk factors for precancer and CCU, describes current methods for the diagnosis of cervical diseases (clinical visual inspection, extended colposcopy, cytology, molecular genetic examination, Digene test, TruScreen, morphological, immunocytochemical, and immunohistochemical studies of the markers p16, Ki67, and anoscopy), and presents the new cytological screening system — the Papanicolau test (Bethesda system). The benefits of drug (immunomodulators) and destructive (ablation and electrical excision) treatments and the possibilities and efficiency of papillomavirus infection and CCU are described in detail.

Full Text

Restricted Access

About the authors

V. N PRILEPSKAYA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: vprilepskaya@mail.ru
Moscow

E. A KOGAN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: e_kogan@oparina4.ru
Moscow

D. Yu TROFIMOV

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: d_trophimov@oparina4.ru
Moscow

References

  1. Сухих Г.Т., Прилепская В.Н., ред. Профилактика рака шейки матки: Руководство для врачей. 3-е изд. М.: МЕДпресс-информ; 2012. 192с.
  2. Роговская С.И. Папилломавирусная инфекция у женщин и патология шейки матки: в помощь практикующему врачу. 2-е изд. М.: ГЭОТАР-Медиа; 2008. 192с.
  3. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D. et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer. 2004; 111(2): 278-85.
  4. Snijders P., van den Brule A., Meijer C. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J. Pathol. 2003; 201(1): 1-6.
  5. Bleotu C., Botezatu A., Goia C.D., Socolov D., Cornifescu F., Teleman S. et al. P16ink4A-A possible marker in HPV persistence screening. Roum. Arch. Microbiol. Immunol. 2009; 68(3): 183-9.
  6. Стерн П.Л., Китченер Г.С., ред. Вакцина для профилактики рака шейки матки: Пер. с англ. Сухих Г.Т., Прилепская В.Н., ред. М.: МЕДпресс-информ; 2009.192с.
  7. Davey E., Barratt A., Irwig L., Chan S.F., Macaskill P., Mannes P., Saville A.M. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet. 2006; 376(9505): 122-32.
  8. Franco E.L., Harper D.M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine. 2005; 23(17-18): 2388-94.
  9. Nuovo J., Melnikow J., Howell L.P. New tests for cervical cancer screening. Am. Fam. Physician. 2001; 64: L780-6.
  10. Pierry D., Weiss G., Lack B., Chen V., Fusco J. Intracellular human papillomavirus E6, E7 mRNA quantification predicts CIN 2+ in cervical biopsies better than Papanicolaou screening for women regardless of age. Arch. Pathol. Lab. Med. 2012; 136(8): 956-60.
  11. UK Department of Health. Report of the cervical screening program. Bulletin 2001/22, September, 2001.
  12. Singer A., Coppleson M., Canfell K., Skladnev V., Mackellar G., Pisal N., Deery A. A real time optoelectronic device as an adjunct to the Pap smear for cervical screening: a multicenter evaluation. Int. J. Gynecol. Cancer. 2003; 13(6): 804-11.
  13. Mayeaux E.J.Jr., Cox J.T., eds. Modern colposcopy: textbook and atlas. 3rd ed. Walters Kluwer; Lippincott Willams & Wilkins; 2012.
  14. Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M. et al.; 2012 ASCCP Consensus Guidelines Conference. 2012 Updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Lower Genit. Tract Dis. 2013; 17(5, Suppl.1):S1-27.
  15. Новиков А.И., Кононов А.В., Ваганова И.Г. Инфекции, передаваемые половым путем, и экзоцервикс. М.: Медицина; 2002. 179с.
  16. Киселев В.И., Аполихина И.А., Муйжнек Е.Л., Денисова Е.Д. Патогенетические подходы к лечению ВПЧ-ассоциированных заболеваний шейки матки. В кн.: Прилепская В.Н., ред. Патология шейки матки и генитальные инфекции. М.: МЕДпресс-информ; 2008: 87-93.
  17. Костава М.Н. Лечение заболеваний шейки матки, обусловленных или сочетающихся с воспалительными процессами нижнего отдела генитального тракта. Гинекология. 2000; 2(3): 89-91.
  18. Сергиенко В.И. ред. Панавир в лечении вирусных инфекций: Сборник «Панавир». М.; 2005: 51-86.
  19. Молочков В.А., Киселев В.И., Рудых И.В., Щербо С.Н. Папилломавирусная инфекция. Клиника, диагностика, лечение: Пособие для врачей. М.: Русский врач; 2004. 44с.
  20. Brotherton J.M., Fridman M., May C.L., Chappell G., Saville A.M., Gertig D.M. et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011; 377 (9783): 2085-92.
  21. Шаханина И.Л., Намазова-Баранова Л.С., Краснопольский В.И., Козаченко В.П., Прилепская В.Н., Щуров Д.Г., Толкушин А.Г. Экономический анализ применения вакцины против вируса папилломы человека в Москве. Эпидемиология и вакцинопрофилактика. 2010; 54(5): 69-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media